140 results found | searching for "investors"

2 3 4 5 6 7 8 9 10 Next Last 
  • vijaykumar0221
  • Suppose you want to plan to invest in Affordable shops in Gurgaon. It is one of the best commercial shops in residential society. This premium project is the perfect place for investors and business people to invest. Also, it is constructed with the latest technology and unique design. The affordable society shops in Gurgaon have furnished all amenities and specifications. Firsly, open parking area in the basement. Secondly, 24 hour water & electricity supply. Thirdly, CCTV surveillance & high-tech security. For More Detail :- 9999-238-238 Visit For Website :- https://key4you.in/shops-in-gurgaon-commercial-society-shops-for-sale-in-gurgaon/
  • ascendbakersfield
  • We provide services for investors who have residential and commercial rental properties. We charge 6% for residential property up to fourplexes. Have peace of mind and total satisfaction. Excellent marketing and exceptional tenant retention, in-house maintenance crew, excellent customer services, and the best rate across all fields. Give us a call to get started, or visit our site to learn more about our services. For more information visit our website : https://ascendbakersfield.com/ [more]
  • zfhoiy8u
  • about it. Basically, a membrane is a thin layer of a unique kind of fabric that could help separate substances in reaction to a driving pressure. Therefore, they are able to assist put off exquisite sorts of https://www.outlookindia.com/outlook-spotlight/golden-revive-plus-reviews-exposed-scam-you-need-to-know-news-223043 https://www.outlookindia.com/outlook-spotlight/fluxactive-complete-reviews-beware-don-t-buy-until-you-see-this-news-223272 https://www.outlookindia.com/outlook-spotlight/protetox-reviews-shocking-scam-revealed-you-need-to-know-news-223348 http://www.myracedb.com.gridhosted.co.uk/apps/wordpress-genesis/uncategorized/disinfectant-to-dry-have-your-spouses-youngsters/ https://www.janubaba.com/c/forum/topic/196388/Rendezvous_aka_Request_service_center_Help_Desk/Sksk https://coub.com/zfhoiy8u https://coub.com/jiyifag344 https://www.bibrave.com/users/173114 https://www.intensedebate.com/people/zfhoiy8u https://www.rolonet.com/posts/122047 https://www.zupyak.com/p/3282755/t/must-get-out-of-your-house https://www.expatriates.com/cls/51552943.html https://www.fxstat.com/en/user/profile/zfhoiy8u-507380 https://regalketo17.lighthouseapp.com/projects/155506-regal-keto/tickets/126-muscle-body-products-at-a-glance https://startupmatcher.com/p/zfhoiy8uzfhoiy8u https://www.carookee.de/forum/Retinoblastom-Forum/32181426?mp=20582027366322fd865939822672885b08aaf1709f35202ea745397&mps=instance%2C+you+may+take+a+look+at#32181426 https://www.bitsdujour.com/view/looking-for-your-selected-product-at#comments60425 https://influence.co/zfhoiy8u https://shortest.activeboard.com/t68775070/celebrities-put-up-their-pix-on-pinterest-understand/?page=last#lastPostAnchor https://www.bibrave.com/users/173120 https://www.bibrave.com/users/173121 https://communities.bentley.com/members/869ad9f9_2d00_8104_2d00_42c2_2d00_833d_2d00_f4b74d21b0f4 https://www.smore.com/n6rgq https://demo.evolutionscript.com/forum/topic/142079-when-you-have-a-warm-the-way-to-Muscle-Body-undertone https://linkhay.com/link/5655961/merchandise-online-hopefully-you-will-discover http://rccanucks.com/showthread.php?4501-lessen-infection-and-the-way-to-Muscle&p=292742#post292742 https://warengo.com/stories/254177-read-at-once-to-discover https://www.viki.com/users/zfhoiy8u_544/about https://quesanswer.com/profile/zfhoiy8u/ https://www.kemovebbs.com/Thread-to-inflammation-According-to-professionals http://www.lawrence.com/users/zfhoiy8u/ https://zfhoiy8u.cookpad-blog.jp/articles/744897?token=794ed26c378af910e78efd340e3793cd8545452b https://www.chordie.com/forum/profile.php?id=1457995 https://www.provenexpert.com/zfhoiy8u/ https://www.vingle.net/posts/4758901 https://myanimelist.net/profile/zfhoiy8u https://www.inkitt.com/zfhoiy8u https://store79418752.company.site/ https://disqus.com/by/zfhoiy8u/about/ http://socialnetwork.linkz.us/posts/34229 https://mymediads.com/articles/151213?new_advert=true http://www.lawrence.com/users/jiyifag344/ https://disqus.com/by/jiyifag344/about/ http://shaobinli.is-programmer.com/posts/421.html https://www.greenandgoldrugby.com/community/members/claill.139137/#about https://www.scoop.it/topic/vayemof194?&kind=crawled&fId=1093105 https://500px.com/photo/1054040169/other-2-by-zfhoiy8u-ladies/ https://works.bepress.com/zfhoiy8u-ladies/ https://activerain.com/blogsview/5750316/energy-if-you-want-to-enhance-your-strength-tiers http://get-simple.info/forums/showthread.php?tid=16764 http://forums.magicengine.com/en/viewtopic.php?p=31362#31362 https://qiita.com/zfhoiy8u/items/654734fdd94e23d04dde https://www.phpbb.com/community/memberlist.php?mode=viewprofile&u=2199211 http://meinriffbecken.siteboard.org/u3957_zfhoiy-u.html https://opencollective.com/zfhoiy8u https://archives.profsurv.com/forum/Professional-Surveyor-Magazine-Discussion/General-Surveying/-106866.aspx https://reefmaster.com.au/index.php/forum/profile/2994-zfhoiy8u http://forum.9dots.de/profile.php?mode=viewprofile&u=19109 https://quickfinds.in/real-estate/real-estate-investors/help-you-make-your-desire_i264161 https://sketchfab.com/zfhoiy8u http://forum.9dots.de/profile.php?mode=viewprofile&u=19110 http://forum.9dots.de/profile.php?mode=viewprofile&u=19111 https://unsplash.com/@vayemof194 https://unsplash.com/@nikabal856 https://unsplash.com/@bihetim100 https://anite1947-02.webselfsite.net/ https://sahulatcenter.com/advert/one-can-pressure-water-via-the/ https://fleming.desire2learn.com/d2l/lms/blog/view_userentry.d2l?ou=6606&ownerId=296&entryId=5&ec=1&iu=1&sp=&gb=usr&emulatemode=1 https://kukooo.com/to-muscle-body/ https://www.b-webdesign.org/dir-wowonder/read-blog/102798 https://gotartwork.com/Blog/to-dispose-of-harmful-factors-best-/53431/ https://kaalama.org/read-blog/175970 https://www.dibiz.com/zfhoiy8u http://foro.testdevelocidadinternet.com/viewtopic.php?f=9&t=1926592&sid=d1c078097ce61ddf837d0dbed11660b0 https://topsitenet.com/profile/zfhoiy8u/878724/ https://topsitenet.com/profile/anite1947/878730/ https://www.callupcontact.com/b/businessprofile/zfhoiy8u/8204074 https://www.behance.net/zfhoiy8uladies https://topsitenet.com/profile/bihetim100/878732/ https://www.apsense.com/user/zfhoiy8u https://creativemarket.com/users/zfhoiy8u https://creativemarket.com/users/podoyah972 https://weheartit.com/zfhoiy8u https://www.authorstream.com/zfhoiy8u/ http://www.zacha-hokej.cz/index.php?m=topic&id=52464 http://www.shadowville.com/board/general-discussions/these-units-can-best-dispose-of-molecules#p550246 http://46543.dynamicboard.de/u20771_zfhoiy-u.html http://bioimagingcore.be/q2a/725841/water-soft-in-the-way-to-muscle-body-quick https://telegra.ph/Just-like-contrary-osmosis-its-miles-a-membrane-09-15 https://openclassrooms.com/en/members/625qx23qx484 https://www.businesslistings.net.au/_health__brain/NT/Nyapari/zfhoiy8u/769557.aspx [more]
  • jameshebrew
  • The Artificial Intelligence in Oncology market is anticipated to grow at a CAGR of 54% claims Roots Analysis The success of currently employed artificial intelligence (AI) solutions has encouraged researchers to explore the potential of such technologies in the healthcare sector, with its prime focus being oncology, to enable the treatment of several prevalent malignancies. London Roots Analysis has announced the addition of “Artificial Intelligence in Oncology Market, 2022-2035” report to its list of offerings. Several AI technologies demonstrating the potential to diagnose precancerous lesions are expected to be capable of reducing mortality rates by improving detection accuracy, speed and providing assistance in clinical decision-making. This is further expected to result in better clinical outcomes. Overall, this domain is anticipated to gain significant traction, in the foreseen future. Key Market Insights Over 76 companies claim to be engaged in the development of AI in oncology software solutions The AI in diagnostics market is dominated by companies based in North America, primarily in the US; of these, majority were established post 2010 and are small firms. Majority of the companies in this domain offer software solutions to hospitals (52%). Nearly 2,770 patents have been filed / granted for AI based software solutions targeting oncology Reflecting the increasing research efforts of several industry players engaged in this domain, around 60% of the patents focused on the AI in oncology domain were filed / granted in North America, primarily in the US. It is also worth noting that the maximum patents were filed (69%) by non-academic players. Partnership activity in this market has increased at a CAGR of 36% over the past five years Technology integration agreements emerged as the most popular type of partnership model adopted by AI in oncology software solution providers, representing over 30% of the total instances. It is worth mentioning that 41% of the partnerships in this domain were inked in 2021. USD 5.9+ billion has been invested by both private and public investors, since 2017 The maximum funding amount was raised through venture capital (66%), grants (11%) and seed funding (8%), during the period 2017-2022. Interestingly, around 86% of the funding instances were reported by players based in the US. Europe is anticipated to capture over 30% of the global market share in 2035 In terms of cancer, the AI in oncology market for solid malignancies is likely to capture the maximum share (33%), followed by the share captured by breast cancer (30%), and this trend is unlikely to change in the foreseen future as well. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/ai-in-oncology-market/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of AI in oncology-based software solutions?  Which type of end-users are primarily employing AI in oncology-based software solutions in their regular workflow?  What kind of partnership models are most commonly being adopted by stakeholders engaged in this domain?  What is the trend for capital investments in this domain?  What are the key strategies that can be implemented by emerging players / start-ups to enter into this highly competitive market?  What is the focus area of big pharma players in this domain?  Which companies are actively filing patents to drive innovation in the field of AI in oncology?  What are the key challenges associated within this domain? The financial opportunity within the AI in oncology market has been analyzed across the following segments:  Type of Cancer  Solid Malignancies  Breast Cancer  Lung Cancer  Prostate Cancer  Colorectal Cancer  Brain Tumor  Others  Type of End-User  Hospitals  Pharma Companies  Research Institutes  Others  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the world The opinions and insights presented in the report were influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:  Jon DeVries (Chief Executive Officer, Mirada Medical)  Piotr Krajewski (Chief Executive Officer, CancerCenter.AI)  Christian Vestergaard Kaltoft (Chief Executive Officer, Visiopharm)  David Wilson (Vice President, Marketing and Communications, Enlitic)  Emily Salerno (Commercial Strategy and Operations Lead, Nucleai) The research includes detailed list of platforms being developed by key players (some of them are listed below); the report features an overview of the platform, details related to the AI technology employed, oncological indication targeted and information related to the type of platform (cloud-based, on-site).  Ibex Medical Analytics  Niramai  Optellum  Tempus Labs  Paige  Kheiron Medical Technologies For additional details, please visit https://www.rootsanalysis.com/reports/ai-in-oncology-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • shakil11
  • These five big transitions are likely to make 2022 a choppy and challenging year for equity investors—and the end of the coronavirus pandemic doesn’t even make the cut. After two years of a pandemic, it might seem strange to warn that the next 12 months are likely to be more difficult for equity investors than the period we’ve just been through. To understand why we believe this, think of 2022 as a year of major inflection points. Some critical technical and fundamental underpinnings of the economy, which have been in place for years or even decades, look set to shift, and it’s likely financial markets will be more volatile as they digest these shifts. Here are the ones we consider most significant. https://megaquery.blogspot.com/2022/08/finance.html [more]
  • jameshebrew
  • The human microbiome market is anticipated to grow at a CAGR of 24% till 2035, claims Roots Analysis With the increasing concept of precision medicine, several scientists have demonstrated interest in the therapeutic manipulation of human microbiome (commonly gut bacteria) for the treatment of a wide range of disease indications. Roots Analysis has announced the addition of “The Human Microbiome Market, (4th Edition) 2022-2035” report to its list of offerings. The microbiome-based therapies pipeline features six drugs in phase III clinical development, over 200 candidates in other clinical and preclinical stages of development along with more than 60 diagnostics and screening / profiling tests that are commercialized for the detection of various diseases. However, the current microbiome market is driven by the fecal microbiota therapies approved by the FDA, particularly for the recurrent CDI and the commercialized diagnostic tests available to the patients. The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. Given the role of microbiota in disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. Key Market Insights Over 230 drug candidates are currently being developed by more than 70 drug developers Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders. More than 75 diagnostics and screening / profiling test are available / under development Of these, around 80% of the tests are available in the market, while rest are under development. More than 40 companies are engaged in providing these tests; these are primarily based in North America (45%) and Europe (39%). It is worth highlighting that majority (68%) of the players are small companies. FMTs are the only commercially available microbiome therapies approved by the FDA These therapies are primarily used for the treatment of recurrent Clostridium difficile infection (rCDIs). It is worth mentioning that more than 400 trials have been registered for evaluating these therapies for a wide range of indications. Partnership activity in this domain has increased at a CAGR of 26%, between 2017 and 2021 Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period. More than USD 1 billion has been invested by both private and public investors, since 2017 Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million. Outsourcing has become an integral part of the microbiome and live biotherapeutics development process Presently, over 25 service providers claim to offer a multitude of contract manufacturing services for microbiome and live biotherapeutic products. It is worth noting that close to 10 firms were established post 2010 and around 45% of the players are located in Europe. Microbiome therapeutics are anticipated to capture more than 60% share of total microbiome market by 2035 As late-stage therapeutics will get approved by the FDA in the foreseen future, the microbiome therapeutics market is likely to grow at an annualized rate of 37% till 2035. It is worth mentioning that microbiome diagnostics is likely to capture 20% of the total microbiome market share by 2035. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/281/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of microbiome therapeutics?  Which are the key microbiome based drugs being developed across various stages of development?  Which companies are actively involved in conducting clinical trials for microbiome therapeutics and FMTs?  Who are the leading players engaged in the development of microbiome diagnostics and screening / profiling tests?  Which types of partnership models are commonly adopted by industry stakeholders?  Who are the key investors in the field of human microbiome therapeutics and diagnostics?  What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?  What is the role of various start-ups engaged in developing human microbiome therapeutics?  Which are the most commonly targeted therapeutic indications for which microbiome therapeutics are being developed?  What are the various steps involved in the manufacturing of microbiome therapeutics?  What are the key considerations for selecting a CMO / CRO for manufacturing of microbiome therapeutics?  What are the various algorithms / tools used to analyze data generated from microbiome research?  How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments?  What are the various non-pharma applications of microbiome products? The financial opportunity within the human microbiome therapeutics market has been analyzed across the following segments:  Type of Product  Probiotic Drugs  Other Drugs  Target Indication  Recurrent C. difficile Infection  Necrotizing Enterocolitis  Primary Hyperoxaluria  Graft versus Host Disease  Therapeutic Area  Infectious Diseases  Digestive and GI Disorders  Rare Disorders  Route of Administration  Oral Route  Rectal Route  Type of Formulation  Capsules  Suspensions  Enemas  Key Geographical Regions  North America  Europe  Asia Pacific The financial opportunity within the human microbiome diagnostics and screening / profiling tests market has been analyzed across the following segments:  Target Indication  Irritable Bowel Syndrome  Inflammatory Bowel Disease  Colorectal Cancer  Diabetes Mellitus  Key Geographical Regions  North America  Europe  Asia Pacific The financial opportunity within the fecal microbiota therapies market has been analyzed across the following segments:  Key Geographical Regions  North America  Europe  Asia Pacific The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the growth of the human microbiome market. It includes detailed transcripts of the discussions held with the senior representatives of the stakeholder firms, including:  Charlie Badham (Senior Manager, Corporate Development, 4D Pharma)  Nicholas Monsul (Co-founder and Chairman, Quorum Innovations)  Alicia Scheffer (Chief Executive Officer, Floragraph)  Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)  Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)  Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)  Assaf Oron (Chief Business Officer, BiomX)  Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories)  Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)  Colleen Cutcliffe (Co-founder and Chief Executive Officer, Pendulum Therapeutics)  Nikole Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics)  James Burges (Ex-Co-founder and Vice President of Innovation, OpenBiome)  Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)  JP Benya (Ex-Vice President, Operations, Assembly Biosciences)  Lee Jones (President and Chief Executive Officer, Rebiotix)  Mark Heiman (Ex-Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics)  Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra) The report also includes detailed profiles of the companies (listed below) engaged in developing microbiome therapeutics, diagnostics and screening / profiling test; each profile features an overview of the company, its financial information (if available), details on its product portfolio, recent developments, and an informed future outlook.  4D Pharma  Biosotia Microbiomics  DNA Genotek  Finch Therapeutics  GoodGut  Infant Bacterial Therapeutics  Invivo Healthcare  MaaT Pharma  OxThera  Qu Biologics  Rebiotix  Seres Therapeutics  Servatus  Shoreline Biome For additional details, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis [more]
  • jameshebrew
  • The needlestick safety injection devices market is anticipated to grow at a commendable pace by 2035, claims Roots Analysis An exponential increase in the annual cost burden due to needlestick injuries, has fueled a corresponding rise in demand for safe and highly advanced safety devices to be developed by the stakeholders engaged in the healthcare industry to generate a stringent regulation for the prevention of needle-stick injuries. Roots Analysis has announced the addition of “Needlestick Safety Injection Devices Market, 2022-2035” report to its list of offerings. Given the inherent benefits of needlestick safety injection devices, number of developers have launched their proprietary devices for minimizing the risk of needlestick injuries. Moreover, stringent regulatory requirements have further prompted the stakeholders to improve product design and integrate better safety measures in their products, including needle shielding. Key Market Insights Currently, around 120 needlestick safety injection devices are available in the market More than 35% of these injection devices are needles having the ability to retract or shield, followed by syringes (30%). It is worth noting that more than 90% of the needlestick safety injection devices are non-reusable (intended for single use) thereby reducing the chances of blood borne pathogen infections. Over 50 companies claim to develop needlestick safety injection devices, worldwide Presently, the market is dominated by very small companies (33%) and small companies (25%). It is worth noting that majority (40%) of the firms engaged in this domain are based in Europe, followed by North America (39%). Partnership activity within this field has grown significantly between 2020 and 2022 Maximum number of partnerships (31%) were established in 2020 indicating a recent rise in the interest of developers engaged in the development of needlestick safety injection devices. It is worth highlighting that majority of the deals were acquisitions. Over USD 260 million has been invested by both private and public investors, since 2016 Companies involved in the development of needlestick safety injection devices have raised around USD 70 million through venture funding, which represents 25% of the total capital raised in the given time period. Overall, around 20 investors have actively financed various projects / initiatives in this domain. Close to 20 global events were organized in the past couple of years in this industry Majority of the events related to needlestick safety injection device were organized in North America (22%). It is worth highlighting that the main agenda of these events was to discuss role of needlestick safety injection devices to prevent the needlestick injuries. More than 140 patents have been filed / granted related to needlestick safety injection devices, since 2018 Of these, over 60 patents were filed / granted in 2022 (till April). Industry players that have filed maximum number of patents related to needlestick safety injection devices include (in decreasing order of number of patents filed) BD, West Pharmaceutical Services, B. Braun, Retractable Technologies and Safety Syringes. North America and Europe are anticipated to capture more than 75% of the market by 2035 Growth in this domain is anticipated to be primarily driven by the rising cases of needlestick injuries amongst the healthcare workers. The Asia-Pacific needlestick safety injection devices market currently accounts for more than 20% of the global market. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/needlestick-safety-market/request-sample.html Key Questions Answered  Who are the leading needlestick safety injection devices developers?  Which are the popular types of safety injection devices available in this market?  What are the key challenges faced by stakeholders engaged in the development of needlestick safety injection devices?  What types of partnership models are commonly being adopted by stakeholders in this industry?  How has the intellectual property landscape of needlestick safety injection devices developers evolved over the years?  Which factors are likely to influence the evolution of this market?  How is the current and future market opportunity likely to be distributed across key market segments? The research also includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.  B. Braun  BD  Gerresheimer  HTL-STREFA  Nipro Europe Group Companies  SOL-MILLENNIUM Medical Group For additional details, please visit https://www.rootsanalysis.com/reports/needlestick-safety-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The gene therapy market is projected to be worth USD 17.3 billion in 2035, growing at a CAGR of 18%, during the period 2022-2035, claims Roots Analysis Given the potential of gene therapies to permanently cure a diverse array of clinical conditions at the genetic level, the current pipeline is rapidly growing; a number of such therapies are currently being evaluated in late stages of development. London Roots Analysis has announced the addition of “Gene Therapy Market (5th Edition), 2022-2035” report to its list of offerings. Post the emergence of blockbuster gene therapies, such as ZOLGENSMA® (for spinal muscular atrophy type I) and Libmeldy™ (for metachromatic leukodystrophy), this domain has garnered significant interest in the medical community. Moreover, considering the promising trial results of pipeline candidates, notable players have made investments to support product development and commercialization efforts. An analysis of the investments made at various stages, such as seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other equity offerings, by gene therapy companies that are engaged. An elaborate discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages and limitations of currently available gene delivery vectors. Key Market Insights Over 1,150 gene therapies are currently being developed across different stages Apart from 11 approved products, most of the aforementioned therapies (70%) are in early stages of development (preclinical / discovery), while the rest are being evaluated in clinical trials. It is worth mentioning that more than 40% of the clinical stage candidates target oncological diseases. Further, majority of such therapies (66%) use adenovirus vectors as molecular carriers. More than 250 companies claim to be engaged in the development of gene therapies, globally In the past decade, over 160 companies have been established in this domain. Of the total, 60% of the players are small firms. In addition, majority (62%) of these gene therapy developers are based in North America, primarily in the US. 290+ clinical trials evaluating gene therapies have been registered, worldwide Of the total number of trials registered during the period 2015-2020, close to 10% have already been completed, while 56% are presently recruiting patients. Further, presently, around 55% of the trials are evaluating therapy candidates in phase II studies. USD 8.5+ billion has been invested by both private and public investors, since 2015 The maximum funding amount was raised through secondary offerings (40%), venture capital (28%) and IPOs (16%), during the period 2015-2022. Interestingly, majority (77%) of the funding instances were reported by players based in North America. Over 5,800 patents have been filed / published related to gene therapies, since 2017 Around 90% of the total number of patent applications were related to gene therapies, while the remaining were focused on gene editing-based therapies. Further, majority of the patent assignees were industry players. However, it is worth mentioning that the contribution of non-industry players in the overall patent filing activity has increased considerably (CAGR of 19%), over the past few years. Merger and acquisition activity in this market has grown at a CAGR of 22%, during 2015-2021 It is worth mentioning that, across most of the instances (43%) both the acquirer and the acquired company were based in North America. Moreover, majority of the acquisitions (26%) were focused on providing access to novel platform / technology, followed by acquisitions undertaken for therapeutic area consolidation (24%) and drug class consolidation (24%). The overall market is anticipated to grow at a CAGR of over 18%, during the period 2022-2035 Gene therapies based on gene augmentation currently represent a significant share of the market, and this trend is unlikely to change in the foreseen future, as several such candidates are being evaluated in late stages. North America (primarily the US) is expected to capture 60% of the market share by 2035, in terms of the sales-based revenues. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/268/request-sample.html Key Questions Answered  Who are the key industry players engaged in the development of gene therapies?  How many gene therapy candidates are currently in the development pipeline? Which key disease indications are targeted by such products?  Which types of vectors are most commonly used for effective delivery of gene therapies?  What are the key regulatory requirements for gene therapy approval, across various geographies?  Which commercialization strategies are most commonly adopted by gene therapy developers, across different stages of the development cycle?  What are the different pricing models and reimbursement strategies currently being adopted for gene therapies?  What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?  Who are the key CMOs / CDMOs engaged in supplying viral / plasmid vectors for gene therapy development?  What are the key value drivers of the merger and acquisition activity in the gene therapy industry?  Who are the key stakeholders that have actively made investments in the gene therapy domain?  Which are the most active trial sites (in terms of number of clinical studies being conducted) for gene therapies?  How is the current and future market opportunity likely to be distributed across key market segments? The financial opportunity within the gene therapy market has been analyzed across the following segments:  Type of Therapy  Gene augmentation  Immunotherapy  Oncolytic viral therapy  Others  Type of Gene Delivery Method Used  Ex vivo  In vivo  Type of Vector Used  Adeno-associated virus  Adenovirus  Herpes simplex virus  Lentivirus  Non-viral vectors  Retrovirus  Others  Target Therapeutic Areas  Cardiovascular diseases  Dermatological diseases  Genetic diseases  Hematological diseases  Infectious diseases  Metabolic diseases  Muscle-related diseases  Oncological diseases  Ophthalmic diseases  Others  Route of Administration  Intraarticular  Intracerebral  Intracoronary  Intradermal  Intralesional  Intramuscular  Intrapleural  Intrathecal  Intratumoral  Intravenous  Intravesical  Intravitreal  Subretinal  Topical  Others  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the World The research includes brief profiles of key players (listed below) engaged in the development of gene therapies; each profile features an overview of the therapy, current development status, clinical trials and its results (if available), target indication, route of administration and recent developments (if available).  Abeona Therapeutics  AGTC  AnGes  Biogen  BioMarin Pharmaceutical  bluebird bio  Castle Creek Biosciences  CG Oncology  FerGene  GenSight Biologics  Helixmith  Holostem Terapie Avanzate  Inovio Pharmaceuticals  Kolon TissueGene  Krystal Biotech  Lysogene  Neurophth Therapeutics  Orchard Therapeutics  Pfizer  PTC Therapeutics  REGENXBIO  Sangamo Therapeutics  Spark Therapeutics  VBL Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • accountantscpa
  • Get the Best Possible Accounting Services for Real Estate Businesses- When you are seeking tax and accounting services for AZ real estate investors, then you must research thoroughly and connect with a well-established CPA firm like Sean Core that has extensive experience in providing accounting services to real estate businesses. Learn more @ https://www.seancorecpa.com/real-estate-cpa/ [more]
  • lendee
  • Investors have to be wary of financial risks as you can't eliminate them entirely. If you are looking to learn ways to minimize them, your search ends here. https://www.lendee.com/financial-risk/
2 3 4 5 6 7 8 9 10 Next Last